Operating in the nutraceuticals and dietary supplements market, Orzax has completed the primary market phase of its transition to public capital. During the bookbuilding transactions managed under the leadership of İnfo Yatırım, the sale of shares with a total nominal value of 52,500,000 TRY was approved.
An analysis of unfiltered demand configurations across allocation groups reveals that domestic institutional investors subscribed to 11.0 times the allocated amount, followed by foreign institutional investors at 3.2 times, domestic retail investors at 1.6 times, and company employees at 1.5 times. Generating a combined unfiltered demand ratio of 4.6 times the total issuance, the Orzax shares were distributed among 974,597 distinct individual and corporate accounts.
Allocation of IPO Proceeds and Corporate Fund Strategies
Evaluating the institutional financial strategy targeted through public capital markets, Orzax CEO Yunus Emre Alimoğlu shared the following details regarding their operational goals:
We are delighted by the confidence our investors have placed in us at this milestone of our journey, which we have sustained with an R&D-focused approach and high-quality standards in the healthcare sector since 2004. Our motto 'Gift to Health' will now reach wider audiences with our new partners. We will utilize a portion of the proceeds generated from the capital increase for new investment financing, R&D center expansions, and our global market growth strategies. The remaining balance will be leveraged to fortify our working capital and enhance our financial efficiency. Our ultimate target is to build a healthier and more sustainable future with our new stakeholders who have joined us during this process.
The company's shares will trade on Borsa Istanbul under the ticker symbol "ORZAX" beginning Tuesday, July 7.
